{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:12:01Z","timestamp":1791058321776,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,1,23]],"date-time":"2010-01-23T00:00:00Z","timestamp":1264204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00280-009-1232-1","type":"journal-article","created":{"date-parts":[[2010,1,22]],"date-time":"2010-01-22T08:37:11Z","timestamp":1264149431000},"page":"869-880","source":"Crossref","is-referenced-by-count":113,"title":["The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo"],"prefix":"10.1007","volume":"66","author":[{"given":"Scott","family":"Ackler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mitten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatol","family":"Oleksijew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Refici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Fesik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul H.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Elmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,23]]},"reference":[{"key":"1232_CR1","unstructured":"SEER Surveillance Epidemiology and End Results [homepage on the internet]. Bethesda: National Cancer Institute; c1973-2007 [updated 18 Dec 2007; cited 2 Jan 2008]. Cancer Stats Fact Sheet, Non-Hodgkin Lymphoma [top of page]. Available from: http:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html"},{"key":"1232_CR2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00003495-200666060-00005","volume":"66","author":"RS Cvetkovic","year":"2006","unstructured":"Cvetkovic RS, Perry CM (2006) Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia. Drugs 66:791\u2013820","journal-title":"Drugs"},{"key":"1232_CR3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","volume":"14","author":"RZ Orlowski","year":"2008","unstructured":"Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14:1649\u20131657","journal-title":"Clin Cancer Res"},{"key":"1232_CR4","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2146\/ajhp070272","volume":"65","author":"KN Utecht","year":"2008","unstructured":"Utecht KN, Kolesar J (2008) Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. Am J Health Syst Pharm 65:1221\u20131231","journal-title":"Am J Health Syst Pharm"},{"key":"1232_CR5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1532\/IJH97.04110","volume":"80","author":"MC Wei","year":"2004","unstructured":"Wei MC (2004) Bcl-2-related genes in lymphoid neoplasia. Int J Hematol 80:205\u2013209","journal-title":"Int J Hematol"},{"key":"1232_CR6","first-page":"9","volume":"34","author":"JC Reed","year":"1997","unstructured":"Reed JC (1997) Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34:9\u201319","journal-title":"Semin Hematol"},{"key":"1232_CR7","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","volume":"226","author":"Y Tsujimoto","year":"1984","unstructured":"Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226:1097\u20131099","journal-title":"Science"},{"key":"1232_CR8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ajh.10139","volume":"70","author":"B Agarwal","year":"2002","unstructured":"Agarwal B, Naresh KN (2002) Bcl-2 family of proteins in indolent B-cell non-Hodgkin\u2019s lymphoma: study of 116 cases. Am J Hematol 70:278\u2013282","journal-title":"Am J Hematol"},{"key":"1232_CR9","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/sj.leu.2401168","volume":"12","author":"N Harada","year":"1998","unstructured":"Harada N, Hata H, Yoshida M et al (1998) Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia 12:1817\u20131820","journal-title":"Leukemia"},{"key":"1232_CR10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503\u2013511","journal-title":"Nature"},{"key":"1232_CR11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2567.2005.02117.x","volume":"114","author":"G Packham","year":"2005","unstructured":"Packham G, Stevenson FK (2005) Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 114:441\u2013449","journal-title":"Immunology"},{"key":"1232_CR12","first-page":"256","volume":"58","author":"Y Tu","year":"1998","unstructured":"Tu Y, Renner S, Xu F et al (1998) Bcl-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 58:256\u2013262","journal-title":"Cancer Res"},{"key":"1232_CR13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1007056727876","volume":"206","author":"S Fukumi","year":"2000","unstructured":"Fukumi S, Horiguchi-Yamada J, Nakada S, Nagai M, Ohno T, Yamada H (2000) Differential responses of Bcl-2 family genes to etoposide in chronic myeloid leukemia K562 cells. Mol Cell Biochem 206:43\u201350","journal-title":"Mol Cell Biochem"},{"key":"1232_CR14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1196\/annals.1378.009","volume":"1090","author":"KV Floros","year":"2006","unstructured":"Floros KV, Thomadaki H, Florou D, Talieri M, Scorilas A (2006) Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Ann N Y Acad Sci 1090:89\u201397","journal-title":"Ann N Y Acad Sci"},{"key":"1232_CR15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/978-1-4615-4811-9_39","volume":"457","author":"R Belhoussine","year":"1999","unstructured":"Belhoussine R, Morjani H, Gillet R, Palissot V, Manfait M (1999) Two distinct modes of oncoprotein expression during apoptosis resistance in vincristine and daunorubicin multidrug-resistant HL60 cells. Adv Exp Med Biol 457:365\u2013381","journal-title":"Adv Exp Med Biol"},{"key":"1232_CR16","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1182\/blood-2007-08-110445","volume":"111","author":"FT Liu","year":"2008","unstructured":"Liu FT, Agrawal SG, Gribben JG et al (2008) Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 111:2797\u20132805","journal-title":"Blood"},{"key":"1232_CR17","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","volume":"67","author":"P Gomez-Bougie","year":"2007","unstructured":"Gomez-Bougie P, Wuilleme-Toumi S, Menoret E et al (2007) Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67:5418\u20135424","journal-title":"Cancer Res"},{"key":"1232_CR18","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","volume":"99","author":"JC Byrd","year":"2002","unstructured":"Byrd JC, Kitada S, Flinn IW et al (2002) The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99:1038\u20131043","journal-title":"Blood"},{"key":"1232_CR19","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421\u20133428","journal-title":"Cancer Res"},{"key":"1232_CR20","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1158\/1535-7163.MCT-08-0268","volume":"7","author":"S Ackler","year":"2008","unstructured":"Ackler S, Xiao Y, Mitten MJ et al (2008) ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 7:3265\u20133274","journal-title":"Mol Cancer Ther"},{"key":"1232_CR21","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/pbc.21433","volume":"50","author":"R Lock","year":"2008","unstructured":"Lock R, Carol H, Houghton PJ et al (2008) Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 50:1181\u20131189","journal-title":"Pediatr Blood Cancer"},{"key":"1232_CR22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","volume":"117","author":"V Del Gaizo Moore","year":"2007","unstructured":"Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117:112\u2013121","journal-title":"J Clin Invest"},{"key":"1232_CR23","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2007-12-130781","volume":"112","author":"L Paoluzzi","year":"2008","unstructured":"Paoluzzi L, Gonen M, Bhagat G et al (2008) The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112:2906\u20132916","journal-title":"Blood"},{"key":"1232_CR24","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2007-03-080325","volume":"110","author":"MH Kang","year":"2007","unstructured":"Kang MH, Kang YH, Szymanska B et al (2007) Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110:2057\u20132066","journal-title":"Blood"},{"key":"1232_CR25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-4598-4-13","volume":"4","author":"RM Mohammad","year":"2005","unstructured":"Mohammad RM, Wang S, Aboukameel A et al (2005) Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-xL [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 4:13\u201321","journal-title":"Mol Cancer Ther"},{"key":"1232_CR26","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.4049\/jimmunol.178.4.2287","volume":"178","author":"AJ Stel","year":"2007","unstructured":"Stel AJ, Ten Cate B, Jacobs S et al (2007) Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol 178:2287\u20132295","journal-title":"J Immunol"},{"key":"1232_CR27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355","journal-title":"Adv Enzyme Regul"},{"key":"1232_CR28","doi-asserted-by":"crossref","first-page":"8731","DOI":"10.1158\/0008-5472.CAN-06-0367","volume":"66","author":"AR Shoemaker","year":"2006","unstructured":"Shoemaker AR, Oleksijew A, Bauch J et al (2006) A small-molecule inhibitor of Bcl-xL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 66:8731\u20138739","journal-title":"Cancer Res"},{"key":"1232_CR29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0163-7258(88)90004-6","volume":"37","author":"NE Sladek","year":"1988","unstructured":"Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37:301\u2013355","journal-title":"Pharmacol Ther"},{"key":"1232_CR30","first-page":"1361","volume":"2","author":"RM Mohammad","year":"2003","unstructured":"Mohammad RM, Al-Katib A, Aboukameel A, Doerge DR, Sarkar F, Kucuk O (2003) Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther 2:1361\u20131368","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 3","key":"1232_CR31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00003495-199958003-00006","volume":"58","author":"FA Greco","year":"1999","unstructured":"Greco FA (1999) Oral etoposide in lymphoma. Drugs 58(Suppl 3):35\u201341","journal-title":"Drugs"},{"key":"1232_CR32","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/0008-5472.CAN-06-2203","volume":"67","author":"SK Tahir","year":"2007","unstructured":"Tahir SK, Yang X, Anderson MG et al (2007) Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 67:1176\u20131183","journal-title":"Cancer Res"},{"key":"1232_CR33","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1038\/sj.onc.1210166","volume":"26","author":"X Lin","year":"2007","unstructured":"Lin X, Morgan-Lappe S, Huang X et al (2007) \u2018Seed\u2019 analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2\/Bcl-xL inhibitor ABT-737. Oncogene 26:3972\u20133979","journal-title":"Oncogene"},{"key":"1232_CR34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva M, Contractor R, Tsao T et al (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375\u2013388","journal-title":"Cancer Cell"},{"key":"1232_CR35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"MF Delft van","year":"2006","unstructured":"van Delft MF, Wei AH, Mason KD et al (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell 10:389\u2013399","journal-title":"Cancer Cell"},{"key":"1232_CR36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/14728222.11.3.363","volume":"11","author":"AM Mandelin II","year":"2007","unstructured":"Mandelin AM II, Pope RM (2007) Myeloid cell leukemia-1 as a therapeutic target. Expert Opin Ther Targets 11:363\u2013373","journal-title":"Expert Opin Ther Targets"},{"key":"1232_CR37","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/carcin\/bgp165","volume":"30","author":"O Kutuk","year":"2009","unstructured":"Kutuk O, Arisan ED, Tezil T, Shoshan MC, Basaga H (2009) Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. Carcinogenesis 30:1517\u20131527","journal-title":"Carcinogenesis"},{"key":"1232_CR38","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1158\/1078-0432.CCR-07-1255","volume":"14","author":"SH Olejniczak","year":"2008","unstructured":"Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS (2008) Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 14:1550\u20131560","journal-title":"Clin Cancer Res"},{"key":"1232_CR39","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","volume":"67","author":"AR Jazirehi","year":"2007","unstructured":"Jazirehi AR, Vega MI, Bonavida B (2007) Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 67:1270\u20131281","journal-title":"Cancer Res"},{"key":"1232_CR40","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/sj.bjc.6603762","volume":"96","author":"M Wobser","year":"2007","unstructured":"Wobser M, Voigt H, Eggert AO et al (2007) Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. Br J Cancer 96:1540\u20131543","journal-title":"Br J Cancer"},{"key":"1232_CR41","first-page":"4950","volume":"6","author":"RM Mohammad","year":"2000","unstructured":"Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM (2000) The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 6:4950\u20134956","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"1232_CR42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/annonc\/5.suppl_1.S61","volume":"5","author":"JC Reed","year":"1994","unstructured":"Reed JC, Kitada S, Takayama S, Miyashita T (1994) Regulation of chemoresistance by the Bcl-2 oncoprotein in non-Hodgkin\u2019s lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5(Suppl 1):61\u201365","journal-title":"Ann Oncol"},{"key":"1232_CR43","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.V86.5.1903.bloodjournal8651903","volume":"86","author":"AJ Minn","year":"1995","unstructured":"Minn AJ, Rudin CM, Boise LH, Thompson CB (1995) Expression of Bcl-xL can confer a multidrug resistance phenotype. Blood 86:1903\u20131910","journal-title":"Blood"},{"key":"1232_CR44","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood.V88.5.1805.1805","volume":"88","author":"Y Tu","year":"1996","unstructured":"Tu Y, Xu FH, Liu J et al (1996) Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 88:1805\u20131812","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1232-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-1232-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1232-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T17:04:08Z","timestamp":1634749448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1232-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,23]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1232-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,23]]}}}